Literature DB >> 19681971

Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients.

Christin C Rogers1, Scott R Johnson, Didier A Mandelbrot, Martha Pavlakis, Timothy Horwedel, Seth J Karp, Ogo Egbuna, James R Rodrigue, Robyn E Chudzinski, Alexander S Goldfarb-Rumyantzev, Douglas W Hanto, Michael P Curry.   

Abstract

The long-term use of calcineurin inhibitors (CNI) leads to renal dysfunction in many liver transplant (LT) recipients. The purpose of this analysis is to evaluate renal function in patients converted from CNI to sirolimus (SRL). From May 2002-November 2006, 137 LT were performed in 125 patients, 72 of which were converted to SRL. Evaluation of SRL conversion was stratified by early conversion (<90 d from LT) (EC) vs. late conversion (LC). Renal function was evaluated using the six-point modification of diet in renal disease formula (estimated glomerular filtration rate [eGFR]). Forty-two patients on SRL and 40 on CNI had at least three months of follow-up and are included in the eGFR evaluation. At all time points after conversion, the EC group demonstrated a significantly higher mean eGFR than those in the LC group. A significant improvement in eGFR was seen within the EC group when comparing eGFR at time of conversion to eGFR at three, six, nine, and 12 months after conversion and last follow-up. The only improvement in the LC group was from conversion to the three-month time point. We conclude that EC to SRL results in a profound improvement in eGFR that begins at three months and is sustained beyond one yr.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19681971     DOI: 10.1111/j.1399-0012.2009.01040.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  6 in total

Review 1.  Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis.

Authors:  Sumeet K Asrani; Michael D Leise; Colin P West; M Hassan Murad; Rachel A Pedersen; Patricia J Erwin; Jianmin Tian; Russell H Wiesner; W Ray Kim
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

2.  Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis.

Authors:  Yuan Kong; Dongping Wang; Yushu Shang; Wenhua Liang; Xiaoting Ling; Zhiyong Guo; Xiaoshun He
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

3.  Cardiorenal benefits of early versus late cyclosporine to sirolimus conversion in a rat model.

Authors:  José Sereno; Ana M Romão; Belmiro Parada; Patrícia Lopes; Eugénia Carvalho; Frederico Teixeira; Flávio Reis
Journal:  J Pharmacol Pharmacother       Date:  2012-04

4.  The benefit of sirolimus maintenance immunosuppression and rabbit antithymocyte globulin induction in liver transplant recipients that develop acute kidney injury in the early postoperative period.

Authors:  Benjamin T Duhart; Winston A Ally; Amy G Krauss; Joanna Q Hudson; James D Eason; Vinaya Rao; Jason M Vanatta
Journal:  J Transplant       Date:  2015-03-11

Review 5.  The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence.

Authors:  Goran B Klintmalm; Björn Nashan
Journal:  J Transplant       Date:  2014-02-25

6.  Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo.

Authors:  Nadiar Mussin; Seung Cheol Oh; Kwang Woong Lee; Min Young Park; Sooin Seo; Nam Joon Yi; Hyeyoung Kim; Kyung Chul Yoon; Sung Woo Ahn; Hyo Sin Kim; Suk Kyun Hong; Dong Kyu Oh; Kyung Suk Suh
Journal:  J Korean Med Sci       Date:  2017-09       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.